LeonaBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
LeonaBio, Inc. (LONA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $2.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-14
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $1.70M, a 26.09% decline year-over-year.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $700.00K, a 70.83% decline year-over-year.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $1.40M, a 22.22% decline year-over-year.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $1.20M, a 53.85% decline year-over-year.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $7.30M, a 33.64% decline from fiscal 2024.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $11.00M, a 12.24% increase from fiscal 2023.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $9.80M, a 44.12% increase from fiscal 2022.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $6.80M, a 385.71% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.40M 10-Q · filed 2026-08-14 | $3.80M derived: sum of 3 quarters · filed 2026-08-14 | $5.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-07 | $2.10M derived: sum of 2 quarters · filed 2026-05-07 | $3.30M derived: sum of 3 quarters · filed 2026-05-07 | $5.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.60M derived: sum of 2 quarters · filed 2026-03-31 | $4.90M derived: sum of 3 quarters · filed 2026-08-14 | $7.30M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.50M derived: sum of 2 quarters · filed 2026-08-14 | $5.90M 10-Q · filed 2025-11-06 | $7.70M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $4.70M 10-Q · filed 2026-08-14 | $6.50M derived: sum of 3 quarters · filed 2026-08-14 | $9.10M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.40M 10-Q · filed 2026-05-07 | $4.20M derived: sum of 2 quarters · filed 2026-05-07 | $6.80M derived: sum of 3 quarters · filed 2026-05-07 | $10.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.40M derived: sum of 2 quarters · filed 2026-03-31 | $8.20M derived: sum of 3 quarters · filed 2026-03-31 | $11.00M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.40M derived: sum of 2 quarters · filed 2025-11-06 | $9.20M 10-Q · filed 2025-11-06 | $10.70M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $6.60M 10-Q · filed 2025-08-07 | $8.10M derived: sum of 3 quarters · filed 2025-08-07 | $10.30M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $2.80M 10-Q · filed 2025-05-09 | $4.30M derived: sum of 2 quarters · filed 2025-05-09 | $6.50M derived: sum of 3 quarters · filed 2025-05-09 | $10.10M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.70M derived: sum of 2 quarters · filed 2025-02-27 | $7.30M derived: sum of 3 quarters · filed 2025-02-27 | $9.80M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.80M derived: sum of 2 quarters · filed 2024-11-07 | $8.30M 10-Q · filed 2024-11-07 | $9.20M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $6.10M 10-Q · filed 2024-08-01 | $7.00M derived: sum of 3 quarters · filed 2024-08-01 | $8.60M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $2.50M 10-Q · filed 2024-05-15 | $3.40M derived: sum of 2 quarters · filed 2024-05-15 | $5.00M derived: sum of 3 quarters · filed 2024-05-15 | $7.40M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.50M derived: sum of 2 quarters · filed 2024-02-22 | $4.90M derived: sum of 3 quarters · filed 2024-02-22 | $6.80M 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.00M derived: sum of 2 quarters · filed 2023-11-09 | $5.90M 10-Q · filed 2023-11-09 | $6.00M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.30M 10-Q · filed 2023-08-10 | $4.40M derived: sum of 3 quarters · filed 2023-08-10 | $5.40M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.90M 10-Q · filed 2023-05-11 | $2.00M derived: sum of 2 quarters · filed 2023-05-11 | $3.00M derived: sum of 3 quarters · filed 2023-05-11 | $3.17M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.10M derived: sum of 2 quarters · filed 2023-03-23 | $1.27M derived: sum of 3 quarters · filed 2023-03-23 | $1.40M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.17M derived: sum of 2 quarters · filed 2022-11-10 | $1.30M 10-Q · filed 2022-11-10 | $1.35M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $297.00K 10-Q · filed 2022-08-15 | $349.00K derived: sum of 3 quarters · filed 2022-08-15 | $444.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $133.00K 10-Q · filed 2022-05-12 | $185.00K derived: sum of 2 quarters · filed 2022-05-12 | $280.00K derived: sum of 3 quarters · filed 2022-05-12 | $318.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $147.00K derived: sum of 2 quarters · filed 2022-03-28 | $185.00K derived: sum of 3 quarters · filed 2022-03-28 | $271.00K 10-K · filed 2022-03-28 |
| 2020-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $133.00K derived: sum of 2 quarters · filed 2021-11-10 | $219.00K 10-Q · filed 2021-11-10 | $279.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $124.00K 10-Q · filed 2021-08-16 | $184.00K derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | $86.00K 10-Q · filed 2021-05-13 | $146.00K derived: sum of 2 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $183.00K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $123.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |